Tony Kouzarides is passionate about ecosystems: well-balanced communities that flourish on mutual and dynamic interactions. But the ecosystems that excite him are not made up of plants, animals and environments. They’re made up of experts.
When a drug fails late on in clinical trials it’s a major setback for launching new medicines. It can cost millions, even billions, of research and development funds. Now, an ‘adaptive’ approach to clinical trials and a genetic tool for predicting success are increasing the odds of picking a winner.
The stirrings of a revolution are starting to ripple through hundreds of laboratories. It’s a revolution that aims to result in new medicines – faster and with fewer failures – and it’s being led by three UK universities and three global pharmaceutical companies.
Researchers are working with pharmaceutical companies to make improvements across the whole supply chain, from how a pill is made to the moment it is swallowed by the patient.
An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline (GSK).
Three global pharmaceutical companies and the technology transfer offices of three world-leading universities – Imperial College London, University College London and the University of Cambridge – have joined forces with a combined £40 million to create the Apollo Therapeutics Fund.
GSK, the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust today announce their Strategic Partnership, with the long-term ambition to jointly deliver new medicine to patients in the next 5-10 years.
Cambridge researchers and pharma in innovative new consortium to develop and study early stage drugs28 Jul 2015
An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.
Cambridge has been part of a successful £16 million bid to work with the MRC, GSK and four other UK universities in a unique open innovation research initiative aiming to improve scientists’ understanding of inflammatory diseases that present a serious burden to patients.
The new threshold for diabetes in pregnancy recently introduced by the UK’s National Institute for Health and Care Excellence (NICE) misses a significant number of women at risk of serious complications, a report published today in the journal Diabetologia shows.